Cargando…
In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is conside...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076477/ https://www.ncbi.nlm.nih.gov/pubmed/25002815 http://dx.doi.org/10.4137/BBI.S15211 |
_version_ | 1782323488934068224 |
---|---|
author | Mathew, Shilu Faheem, Muhammad Archunan, Govindaraju Ilyas, Muhammad Begum, Nargis Jahangir, Syed Qadri, Ishtiaq Qahtani, Mohammad Al Mathew, Shiny |
author_facet | Mathew, Shilu Faheem, Muhammad Archunan, Govindaraju Ilyas, Muhammad Begum, Nargis Jahangir, Syed Qadri, Ishtiaq Qahtani, Mohammad Al Mathew, Shiny |
author_sort | Mathew, Shilu |
collection | PubMed |
description | Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is considered to be the superlative target of antiviral compounds. Novel drug inhibitors of HCV are in need to complement or replace the current treatments such as pegylated interferon’s and ribavirin as they are partially booming and beset with various side effects. Our study was conducted to predict 3D structure of capsid core protein of HCV from northern part of India. Core, the capsid protein of HCV, handles the assembly and packaging of HCV RNA genome and is the least variable of all the ten HCV proteins among the six HCV genotypes. Therefore, we screened four phytochemicals inhibitors that are known to disrupt the interactions of core and other HCV proteins such as (a) epigallocatechin gallate (EGCG), (b) ladanein, (c) naringenin, and (d) silybin extracted from medicinal plants; targeted against active site of residues of HCV-genotype 3 (G3) (Q68867) and its subtypes 3b (Q68861) and 3g (Q68865) from north India. To study the inhibitory activity of the recruited flavonoids, we conducted a quantitative structure–activity relationship (QSAR). Furthermore, docking interaction suggests that EGCG showed a maximum number of hydrogen bond (H-bond) interactions with all the three modeled capsid proteins with high interaction energy followed by naringenin and silybin. Thus, our results strongly correlate the inhibitory activity of the selected bioflavonoid. Finally, the dynamic predicted capsid protein molecule of HCV virion provides a general avenue to target structure-based antiviral compounds that support the hypothesis that the screened inhibitors for viral capsid might constitute new class of potent agents but further confirmation is necessary using in vitro and in vivo studies. |
format | Online Article Text |
id | pubmed-4076477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-40764772014-07-07 In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India Mathew, Shilu Faheem, Muhammad Archunan, Govindaraju Ilyas, Muhammad Begum, Nargis Jahangir, Syed Qadri, Ishtiaq Qahtani, Mohammad Al Mathew, Shiny Bioinform Biol Insights Original Research Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is considered to be the superlative target of antiviral compounds. Novel drug inhibitors of HCV are in need to complement or replace the current treatments such as pegylated interferon’s and ribavirin as they are partially booming and beset with various side effects. Our study was conducted to predict 3D structure of capsid core protein of HCV from northern part of India. Core, the capsid protein of HCV, handles the assembly and packaging of HCV RNA genome and is the least variable of all the ten HCV proteins among the six HCV genotypes. Therefore, we screened four phytochemicals inhibitors that are known to disrupt the interactions of core and other HCV proteins such as (a) epigallocatechin gallate (EGCG), (b) ladanein, (c) naringenin, and (d) silybin extracted from medicinal plants; targeted against active site of residues of HCV-genotype 3 (G3) (Q68867) and its subtypes 3b (Q68861) and 3g (Q68865) from north India. To study the inhibitory activity of the recruited flavonoids, we conducted a quantitative structure–activity relationship (QSAR). Furthermore, docking interaction suggests that EGCG showed a maximum number of hydrogen bond (H-bond) interactions with all the three modeled capsid proteins with high interaction energy followed by naringenin and silybin. Thus, our results strongly correlate the inhibitory activity of the selected bioflavonoid. Finally, the dynamic predicted capsid protein molecule of HCV virion provides a general avenue to target structure-based antiviral compounds that support the hypothesis that the screened inhibitors for viral capsid might constitute new class of potent agents but further confirmation is necessary using in vitro and in vivo studies. Libertas Academica 2014-06-23 /pmc/articles/PMC4076477/ /pubmed/25002815 http://dx.doi.org/10.4137/BBI.S15211 Text en © 2014 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License. |
spellingShingle | Original Research Mathew, Shilu Faheem, Muhammad Archunan, Govindaraju Ilyas, Muhammad Begum, Nargis Jahangir, Syed Qadri, Ishtiaq Qahtani, Mohammad Al Mathew, Shiny In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India |
title | In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India |
title_full | In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India |
title_fullStr | In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India |
title_full_unstemmed | In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India |
title_short | In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India |
title_sort | in silico studies of medicinal compounds against hepatitis c capsid protein from north india |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076477/ https://www.ncbi.nlm.nih.gov/pubmed/25002815 http://dx.doi.org/10.4137/BBI.S15211 |
work_keys_str_mv | AT mathewshilu insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT faheemmuhammad insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT archunangovindaraju insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT ilyasmuhammad insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT begumnargis insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT jahangirsyed insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT qadriishtiaq insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT qahtanimohammadal insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia AT mathewshiny insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia |